mRNA Therapeutics Market To Reach $139.01 billion by 2033

The report “mRNA Therapeutics Market by Application (Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, and Others), By Type (Prophylactic, Therapeutic), By End-User (Hospitals & Clinics, Research Organizations, and Others)” is expected to reach USD 139.01 billion by 2033, registering a CAGR of 13.30% from 2026 to 2033, according to a new report by Transpire Insight.

This is fueled by continued advancements in lipid nanoparticle delivery technologies, the design of mRNA by AI technologies, and an increased focus on R&D expenditures that improve the efficacy of therapeutics. The support of regulatory policies and an expansion of clinical trials further accelerate the adaptation of personalized medicine. As stated by the WHO, there were 20 million new cases of cancer and close to 10 million deaths due to cancer in 2022. The advancements in gene editing technologies and protein replacement further expand the horizon of mRNA therapeutics; moreover, more than US$5 billion is being invested by leaders in the R&D space to develop mature pipelines. Highly advanced delivery systems, especially lipid nanoparticles (LNPs), have improved mRNA stability and targeting, and these are essential for therapeutic efficacy. Technological innovations have minimized the mRNA immune response and degradation, and thus improved safety. On the other hand, AI is transforming the designs of the mRNA sequence by analyzing its stability and immune response, and thereby reducing the development process by 30%. Technological innovations in manufacturing, such as microfluidics and automation, are lowering the cost of production by over 15% each year. There are also pilot projects within the regulations for the development of medications using AI.

The Infectious Diseases segment is projected to witness the highest CAGR in the mRNA Therapeutics Market during the forecast period.

Infectious diseases still hold the leading position in terms of application for mRNA therapy, and this segment accounts for a 60% market revenue share in 2025. It is a result of the requirement for vaccines for COVID-19 variants and preventive vaccines for viral infections, including respiratory syncytial virus and influenza.

The Prophylactic segment is projected to witness the highest CAGR in the mRNA Therapeutics Market during the forecast period.

This dominance is essentially because of the mRNA vaccines being used for the prevention of infectious diseases, where development, manufacturing, and protection from the immune system are very important. Preventive usage is highly supported by the government, and immunization is conducted all around the globe. This is higher in comparison to the usage in the case of therapeutic mRNA, which is currently in the clinical stage.

The Hospitals & clinics segment is projected to witness the highest CAGR in the mRNA Therapeutics Market during the forecast period.

The dominance in the field is primarily because of mRNA products, especially vaccines, which are administered to patients directly through hospitals and clinics. The required infrastructure for storage and large-scale immunization programs is also present in hospitals and clinics. Moreover, hospitals and clinics are right in the middle of patients and serve as the prime point of use for mRNA therapeutic products and, hence, have direct dominance over research organizations and end-users.

The North America region is projected to witness the highest CAGR in the mRNA Therapeutics Market during the forecast period.

The North America region is going to see the growth in the mRNA Therapeutics Market over the next few years. This means that the mRNA Therapeutics Market in the North America region will grow faster than in places. The North America region will have the growth rate, in the mRNA Therapeutics Market during this time.

The mRNA therapies market in North America is doing well. It is expected to have around 40.0% of the market share by 2025. The main reason for this is the United States, which has a good healthcare system. The US also gives a lot of money than US$10 Billion every year to help this market grow. The rules and regulations in the US are also helpful because the FDA is involved. The COVID-19 pandemic helped the mRNA technology become more popular. This created an environment for companies like Moderna, Pfizer and BioNTech to innovate and come up with new ideas. The mRNA therapies market is really strong, in North America because of this.

The North America market is expected to grow at a CAGR of 14.0% over the period 2025 to 2032, driven by the continued growth of clinical programs within oncology and the development of personalized medicines. The robust cold chain infrastructure and investments made in scaling up bio manufactures have contributed significantly to the regular supply capacities. In addition, partnership ventures between academic and government or industrial facilities have catalysed therapeutic innovations that continue to ensure growth within this region.

Key Players

The top 15 players in the mRNA Therapeutics Market include Moderna Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Sanofi, GSK Plc., Argos Therapeutics Inc., Ethris, Pfizer Inc., AstraZeneca.

Drop us an email at:

inquiry@transpireinsight.com

Call us on:

+91 7666513636